Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolastatin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia
NCT00005579Phase 2Completed
- Sponsor
- The University of Vermont
- Start
- Jun 1998
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolastatin 10 in lymphoma, Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), sponsored by The University of Vermont. Started Jun 1998; status: completed.
02
Drugs
dolastatin 10
03
Conditions
lymphomaWaldenström macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00005579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005579.